Karlsson MO - Search Results

1

Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study.

Krishnan SM, Friberg LE, Mercier F, Zhang R, Wu B, Jin JY, Hoang T, Ballinger M, Bruno R, Karlsson MO. Krishnan SM, et al. Among authors: karlsson mo. Clin Pharmacol Ther. 2023 Apr;113(4):851-858. doi: 10.1002/cpt.2838. Epub 2023 Jan 29. Clin Pharmacol Ther. 2023. PMID: 36606486

2

A population model for the leukopenic effect of etoposide.

Karlsson MO, Port RE, Ratain MJ, Sheiner LB. Karlsson MO, et al. Clin Pharmacol Ther. 1995 Mar;57(3):325-34. doi: 10.1016/0009-9236(95)90158-2. Clin Pharmacol Ther. 1995. PMID: 7697950

3

Estimating bioavailability when clearance varies with time.

Karlsson MO, Sheiner LB. Karlsson MO, et al. Clin Pharmacol Ther. 1994 Jun;55(6):623-37. doi: 10.1038/clpt.1994.79. Clin Pharmacol Ther. 1994. PMID: 8004879

4

Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.

Friberg LE, Freijs A, Sandström M, Karlsson MO. Friberg LE, et al. Among authors: karlsson mo. J Pharmacol Exp Ther. 2000 Nov;295(2):734-40. J Pharmacol Exp Ther. 2000. PMID: 11046112

5

Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats.

Jonsson E, Friberg LE, Karlsson MO, Hassan SB, Freijs A, Hansen K, Larsson R. Jonsson E, et al. Among authors: karlsson mo. Cancer Chemother Pharmacol. 2000;46(6):493-500. doi: 10.1007/s002800000181. Cancer Chemother Pharmacol. 2000. PMID: 11138463

6

In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients.

Jonsson E, Friberg LE, Karlsson MO, Hassan SB, Nygren P, Kristensen J, Tholander B, Binderup L, Larsson R. Jonsson E, et al. Among authors: karlsson mo. Cancer Lett. 2001 Jan 26;162(2):193-200. doi: 10.1016/s0304-3835(00)00661-3. Cancer Lett. 2001. PMID: 11146225

7

Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC).

Friberg LE, Brindley CJ, Karlsson MO, Devlin AJ. Friberg LE, et al. Among authors: karlsson mo. Eur J Clin Pharmacol. 2000 Nov;56(8):567-74. doi: 10.1007/s002280000181. Eur J Clin Pharmacol. 2000. PMID: 11151746

8

Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Friberg LE, et al. Among authors: karlsson mo. J Clin Oncol. 2002 Dec 15;20(24):4713-21. doi: 10.1200/JCO.2002.02.140. J Clin Oncol. 2002. PMID: 12488418

9

Mechanistic models for myelosuppression.

Friberg LE, Karlsson MO. Friberg LE, et al. Among authors: karlsson mo. Invest New Drugs. 2003 May;21(2):183-94. doi: 10.1023/a:1023573429626. Invest New Drugs. 2003. PMID: 12889739 Review.

10

Pharmacokinetic/pharmacodynamic modelling in oncological drug development.

Karlsson MO, Anehall T, Friberg LE, Henningsson A, Kloft C, Sandström M, Xie R. Karlsson MO, et al. Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):206-11. doi: 10.1111/j.1742-7843.2005.pto960310.x. Basic Clin Pharmacol Toxicol. 2005. PMID: 15733216 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

435 results

Search Page

Filters